Tuesday, 29 July 2014

Novo Nordisk receives positive opinion on Xultophy® (IDegLira) from the European regulatory authorities

Xultophy® is the intended brand name for IDegLira, the first once-daily single injection combination of Tresiba® (insulin degludec) and Victoza® (liraglutide), developed for the treatment of type 2 diabetes. EMA summary of opinion (Novo Nordisk)


Bariatric Surgery Induces Weight Loss but Does Not Improve Glycemic Control in Patients With Type 1 Diabetes

However, the small sample size and limited time of follow-up of this latest and other previous reports preclude drawing firm conclusions (Diabetes Care)


Potential of Oncostatin M to accelerate diabetic wound healing

The results of this study indicate that topical application of OSM may have the potential to accelerate healing of diabetic wounds (Internal Wound Journal)

No comments:

Post a Comment